Canadian Agency for Drugs and Technologies in Health. (2020). CADTH reimbursement recommendation: Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency). Emicizumab (Hemlibra). Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Hoffmann-La Roche Ltd. : Indication: Bleeding Prevention, Hemophilia A (congenital Factor VIII Deficiency). Emicizumab (Hemlibra). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2020.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Hoffmann-La Roche Ltd. : Indication: Bleeding Prevention, Hemophilia A (congenital Factor VIII Deficiency). Emicizumab (Hemlibra). Canadian Agency for Drugs and Technologies in Health, 2020.
